Abbott Laboratories Management

Management Kriterienprüfungen 3/4

Abbott Laboratories CEO ist Robert Ford , ernannt in Oct 2018, hat eine Amtszeit von 6.08 Jahren. Die jährliche Gesamtvergütung beträgt $23.27M , bestehend aus 6.4% Gehalt und 93.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.024% der Aktien des Unternehmens, im Wert von CHF43.05M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.8 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

Robert Ford

Geschäftsführender

US$23.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.4%
Amtszeit als Geschäftsführer	6.1yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	5.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Robert Ford im Vergleich zu den Einnahmen von Abbott Laboratories verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Vergütung im Vergleich zum Markt: RobertDie Gesamtvergütung ($USD23.27M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Swiss ($USD4.75M).

Entschädigung vs. Einkommen: RobertDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Robert Ford (50 yo)

6.1yrs

Amtszeit

US$23,268,171

Vergütung

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Ford	Chairman of the Board	6.1yrs	US$23.27m	0.024% CHF 43.1m
Philip Boudreau	CFO & Executive VP of Finance	1.2yrs	US$3.32m	0.0023% CHF 4.1m
Hubert Allen	Executive VP	11.8yrs	US$7.42m	0.011% CHF 19.0m
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10.2yrs	US$5.93m	0.0073% CHF 13.0m
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.8yrs	US$5.50m	0.0035% CHF 6.3m
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	keine Daten	keine Daten
Michael Comilla	Vice President of Investor Relations.	no data	keine Daten	keine Daten
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	keine Daten	keine Daten
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	keine Daten	keine Daten
Christopher Scoggins	Senior Vice President of Commercial Operations	1.8yrs	keine Daten	keine Daten
Mary Moreland	Executive Vice President of Human Resources	5.3yrs	keine Daten	0.0059% CHF 10.6m
Jared Watkin	Executive Vice President of Diabetes Care	9.4yrs	keine Daten	0.0042% CHF 7.4m

5.8yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: ABTDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.8 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Robert Ford	Chairman of the Board	5yrs	US$23.27m	0.024% CHF 43.1m
Daniel Starks	Independent Director	7.8yrs	US$349.29k	0.39% CHF 692.0m
John Stratton	Independent Director	7.8yrs	US$341.96k	0.00020% CHF 357.7k
Nancy McKinstry	Lead Independent Director	12.9yrs	US$405.96k	0.00027% CHF 482.9k
Michael Roman	Independent Director	3.6yrs	US$337.96k	0% CHF 0
Robert Alpern	Independent Director	16.1yrs	US$441.44k	0% CHF 0
Michael O'Grady	Independent Director	1.6yrs	US$283.96k	0% CHF 0
Michelle Kumbier	Independent Director	6.4yrs	US$331.96k	0.00018% CHF 322.0k
Sally Blount	Independent Director	12.9yrs	US$362.60k	0.00015% CHF 268.3k
Claire Babineaux-Fontenot	Independent Director	2.2yrs	US$354.96k	0% CHF 0
Darren McDew	Independent Director	5.2yrs	US$331.19k	0% CHF 0
Patricia Gonzalez	Independent Director	3.3yrs	US$356.96k	0% CHF 0

5.8yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: ABTDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Abbott Laboratories Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Insider recently sold CHF2.2m worth of stock

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Independent Director recently sold CHF4.2m worth of stock

Recent updates

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Upcoming dividend of US$0.55 per share

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Second quarter 2024 earnings released: EPS: US$0.74 (vs US$0.79 in 2Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

First quarter dividend of US$0.55 announced

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Insider recently sold CHF2.2m worth of stock

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.76 in 1Q 2023)

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.75 in 1Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Fourth quarter dividend of US$0.55 announced

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings released: EPS: US$3.27 (vs US$3.94 in FY 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Upcoming dividend of US$0.55 per share at 2.0% yield

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold CHF4.2m worth of stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.81 in 3Q 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Upcoming dividend of US$0.51 per share at 2.1% yield

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter